Compare BCC & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BCC | TLX |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | United States | Australia |
| Employees | 7680 | N/A |
| Industry | RETAIL: Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.2B |
| IPO Year | 2012 | N/A |
| Metric | BCC | TLX |
|---|---|---|
| Price | $79.08 | $9.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $105.67 | $21.13 |
| AVG Volume (30 Days) | ★ 372.3K | 203.6K |
| Earning Date | 05-04-2026 | 04-17-2026 |
| Dividend Yield | ★ 1.18% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.53 | N/A |
| Revenue | ★ $4,995,290,000.00 | N/A |
| Revenue This Year | $3.66 | N/A |
| Revenue Next Year | $4.76 | N/A |
| P/E Ratio | ★ $21.15 | $150.33 |
| Revenue Growth | ★ 12.71 | N/A |
| 52 Week Low | $65.14 | $6.28 |
| 52 Week High | $98.20 | $19.93 |
| Indicator | BCC | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 59.01 | 67.89 |
| Support Level | $78.56 | $9.46 |
| Resistance Level | $78.96 | $9.92 |
| Average True Range (ATR) | 2.48 | 0.28 |
| MACD | 0.84 | 0.05 |
| Stochastic Oscillator | 86.98 | 87.84 |
Boise Cascade Co is a producer of engineered wood products (EWP) and plywood. The firm operates in two reportable segments, namely Wood Products and Building Materials Distribution. The Wood Products segment manufactures laminated veneer lumber (LVL), I-joists, and laminated beams. In addition, it manufactures structural, appearance, and industrial-grade plywood panels, and ponderosa pine lumber. The Building Materials Distribution segment is engaged in the distribution of various building materials, including oriented strand board (OSB), plywood, and lumber; general line items such as siding, composite decking, doors and millwork, metal products, roofing, and insulation; and EWP, among others. The company generates a majority of its revenue from the Building Material Distribution segment.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.